Design Therapeutics (DSGN) Assets Average (2021 - 2026)
Design Therapeutics (DSGN) posted quarterly Assets Average of $222.8 million for Q2 2026, down 3.21% year-over-year from $230.2 million in Q2 2025, and down 2.43% on a QoQ basis from $228.3 million in Q1 2026.
Design Therapeutics (DSGN) Assets Average (2021 - 2026) Analysis & Trends
Design Therapeutics has reported Assets Average for 6 years, with the latest figure at $222.8 million in Q2 2026.
- Assets Average for Q2 2026 came in at $222.8 million, down 3.21% year-over-year; the trailing twelve-month figure through Jun 2026 was $222.8 million (down 3.21% YoY), and the FY2025 annual result was $239.1 million, down 11.71% from the prior year.
- Assets Average eased to $222.8 million in Q2 2026, from $228.3 million in the prior quarter.
- Over five years, Assets Average peaked at $384.7 million in Q1 2022 and troughed at $217.3 million in Q3 2025.
- A 5-year average of $286.8 million and a median of $279.2 million in 2024 frame the typical range for Assets Average.
- The widest annual swing landed in 2022, when Assets Average surged 71.59%; it then declined 18.18% in 2025.
- A 5-year view of Assets Average shows it stood at $347.9 million in 2022, then slipped by 15.26% to $294.8 million in 2023, then decreased by 12.86% to $256.9 million in 2024, then declined by 14.75% to $219.0 million in 2025, then grew by 1.73% to $222.8 million in 2026.
- Per Business Quant data, the three most recent Assets Average figures were $222.8 million in Q2 2026, $228.3 million in Q1 2026, and $219.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - | 222.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 222.79 Mn |
| Mar 31, 2026 | 228.32 Mn |
| Dec 31, 2025 | 218.99 Mn |
| Sep 30, 2025 | 217.33 Mn |
| Jun 30, 2025 | 230.18 Mn |
| Mar 31, 2025 | 244.78 Mn |
| Dec 31, 2024 | 256.86 Mn |
| Sep 30, 2024 | 265.61 Mn |
| Jun 30, 2024 | 274.19 Mn |
| Mar 31, 2024 | 284.22 Mn |
| Dec 31, 2023 | 294.76 Mn |
| Sep 30, 2023 | 305.75 Mn |
| Jun 30, 2023 | 318.19 Mn |
| Mar 31, 2023 | 332.94 Mn |
| Dec 31, 2022 | 347.85 Mn |
| Sep 30, 2022 | 361.25 Mn |
| Jun 30, 2022 | 373.37 Mn |
| Mar 31, 2022 | 384.68 Mn |
| Dec 31, 2021 | 395.46 Mn |
| Sep 30, 2021 | 402.75 Mn |